cancerletter.com
FDA final guidance on psychedelics opens the door to psycho-oncology research Guidance permits treatment without psychotherapy, alarming scientists, advocates - The Cancer Letter
FDA has released a final guidance for drug sponsors conducting clinical trials of psychedelics, including psilocybin, LSD, and MDMA, for the treatment of psychiatric and substance abuse disorders. To access this subscriber-only content please log in or subscribe.If your institution has a site license, log in with IP-login or register for a sponsored account.**Not all [âŠ]